Get started
Author

François Poumeaud

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
2024 · F. Poumeaud, M. Morisseau, et al. · British Journal of Cancer · 73
PDF
Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System
2019 · Pierre Antoine Faye, François Poumeaud, et al. · Frontiers in Neuroscience · 37
PDF
Focus on cell therapy to treat corneal endothelial diseases
2021 · Pierre Antoine Faye, François Poumeaud, et al. · Experimental Eye Research · 36
PDF
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer
2024 · Jean-Sebastien Frenel, Jean Zeghondy, et al. · JAMA Network Open · 23
PDF
Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy
2024 · F. Poumeaud, T. Valentin, et al. · European Journal of Cancer · 16
Abstract PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
2024 · François Poumeaud, Mathilde Morisseau, et al. · Cancer Research · 16
Pharmacoresistant Epilepsy in Childhood: Think of the Cerebral Folate Deficiency, a Treatable Disease
2020 · Sarah Mafi, Cécile Laroche-Raynaud, et al. · Brain Sciences · 16
PDF
Special features of sarcomas developed in patients with Lynch syndrome: A systematic review
2023 · François Poumeaud, Thibaud Valentin, et al. · Critical Reviews in Oncology/Hematology · 13
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.
2023 · Jean-Sebastien Frenel, Jean Zeghondy, et al. · Journal of Clinical Oncology · 11
PDF
Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome
2021 · François Poumeaud, Clotilde Mircher, et al. · Neurobiology of Stress · 11
PDF
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC+
2025 · C. Cuvelier, M. Brahmi, et al. · ESMO Open · 8
PDF
Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
2022 · François Poumeaud, Anna Fontanier, et al. · Frontiers in Oncology · 6
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review
2024 · François Poumeaud, Marion Jaffrelot, et al. · Frontiers in Medicine · 4
Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report
2023 · François Poumeaud, Florence Dalenc, et al. · JCO Precision Oncology · 4
312P Efficacy of sequential antibody-drug conjugates (ADCs) targeting topoisomerase-1 in HER2-low metastatic breast cancer (MBC): Updated results and additional analyses from the French multicenter retrospective ADC-low cohort
2025 · F. Poumeaud, M. Morisseau, et al. · ESMO Open · 3
PDF
EWSR1::CREM rearranged intra-abdominal malignant epithelioid neoplasm: two new cases of an emerging entity with clinicopathological characteristics and histological pitfalls
2025 · Mariam Rusidzé, François Poumeaud, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 3
PDF
Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort.
2025 · Jean-Sebastien Frenel, Jean Zeghondy, et al. · Journal of Clinical Oncology · 2
Abstract PD3-08: Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort
2026 · F. Poumeaud, M. Morisseau, et al. · Clinical Cancer Research · 1
Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study
2026 · Olivia Lavigne, François Poumeaud, et al. · Breast Cancer Research and Treatment · 1
Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
2026 · Jean-Louis Lacaze, Bastien Cabarrou, et al. · The Oncologist
PDF
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
2026 · JeanSebastien Frenel, Alexandre de Nonnevile, et al. · The Breast
PDF
Triple-negative oligometastatic breast cancer: A retrospective cohort.
2026 · Jean Louis Lacaze, Bastien Cabarrou, et al. · Journal of Clinical Oncology
53P Molecular landscape and clinical outcome of early relapsed metastatic triple-negative breast cancer (mTNBC)
2026 · T. Ruelle, A. Lourdessamy, et al. · ESMO Open
470P Real-world safety and effectiveness of sacituzumab govitecan in older patients with HR+/HER2- and triple-negative advanced breast cancer: The S-GOLD study
2026 · B. Poirier, A.A. Viansone, et al. · ESMO Open
Abstract PS5-01-22: Efficacy of second- or third-line Tucatinib, Trastuzumab, and Capecitabine (TTC) following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer: A multicenter French cohort study
2026 · J. S. Frenel, A. de Nonnevile, et al. · Clinical Cancer Research
Works count: 34
Citation count: 284
H-index: 10
I10-index: 10
Year
Topic
Type